We assume no obligation to update these statements as circumstances change. So you should not place undue reliance on these statements. Actual results or events could differ materially. We may not actually achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statements. These statements are based on information available to us today, April 30, 2020. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of VASCEPA prescriptions, VASCEPA product and licensing revenues, costs and other commercial metrics and gross margin our current plans and expectations regarding spending, including expenditures for the purchase of additional supply of VASCEPA our current expectations regarding the adequacy of our financial resources our current plans and expectations for product revenue growth and product promotion in light of COVID-19 and any potential for added cardiovascular risk attention to VASCEPA as a result of COVID-19 our current plans and expectations regarding appealing the District Court VASCEPA related patent litigation decision to the Federal Circuit and our current plans and expectations for a potential launch of generic versions of VASCEPA by generic companies and by ourselves, including expectations regarding ANDA approvals by the FDA generic cost-effective supply availability timing, potential levels of damages and ability to recover VASCEPA growth if the appeal succeeds our current expectations for regulatory reviews outside the United States regarding VASCEPA approval and regulatory reviews inside the United States regarding consumer promotion and related timing thereof our expectations regarding sales force productivity our goals regarding the timing, scope and success of international expansion, including expectations regarding our ability to launch VASCEPA in Europe directly or through a potential partner and our expectations for clinical trial results in China and our current plans for commercial expansion in the United States with and without entry of potential generic competition. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |